{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23"],"submitter":["Kwag E"],"pubmed_abstract":["<h4>Background</h4>Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has shown superior efficacy over traditional chemotherapy in NSCLC treatment. However, issues like secondary resistance and adverse effects call for alternative therapies. HAD-B1, comprising 4 herbal medicines, has shown promise in lung cancer treatment in both preclinical and clinical settings. This study assesses the combination of HAD-B1 and Afatinib in advanced NSCLC patients to potentially improve outcomes by addressing the limitations of current EGFR-TKI therapies.<h4>Method</h4>A randomized, open-label trial evaluated the efficacy and"],"journal":["Integrative cancer therapies"],"pagination":["15347354241268231"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11301725"],"repository":["biostudies-literature"],"pubmed_title":["A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations."],"pmcid":["PMC11301725"],"pubmed_authors":["Kwag E","Lee S","Jeong MK","Bang SH","Son JW","Shin SH","Hoon Yoon S","Choi JY","Kim SD","Oak C","Woo Lee H","Yoo HS","Park SJ","Kang IC","Kim SJ"],"additional_accession":[]},"is_claimable":false,"name":"A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations.","description":"<h4>Background</h4>Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has shown superior efficacy over traditional chemotherapy in NSCLC treatment. However, issues like secondary resistance and adverse effects call for alternative therapies. HAD-B1, comprising 4 herbal medicines, has shown promise in lung cancer treatment in both preclinical and clinical settings. This study assesses the combination of HAD-B1 and Afatinib in advanced NSCLC patients to potentially improve outcomes by addressing the limitations of current EGFR-TKI therapies.<h4>Method</h4>A randomized, open-label trial evaluated the efficacy and","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan-Dec","modification":"2025-04-06T03:43:39.022Z","creation":"2025-04-06T03:43:39.022Z"},"accession":"S-EPMC11301725","cross_references":{"pubmed":["39103991"],"doi":["10.1177/15347354241268231"]}}